Format
Items per page

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Multiple myeloma

Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). [from OMIM]

MedGen UID:
10122
Concept ID:
C0026764
Neoplastic Process
2.

Multiple myeloma

A malignant plasma cell tumor growing within soft tissue or within the skeleton. [from HPO]

MedGen UID:
505979
Concept ID:
CN005898
Finding
3.

panobinostat

A drug being studied in the treatment of cancer. It blocks enzymes needed for cells to grow and divide and may kill cancer cells. LBH589 may also prevent the growth of new blood vessels that tumors need to grow. It is a type of histone deacetylase inhibitor and a type of antiangiogenesis agent. [from NCI]

MedGen UID:
372685
Concept ID:
C1998098
Amino Acid, Peptide, or Protein; Enzyme; Organic Chemical; Pharmacologic Substance
4.

LBH589

MedGen UID:
290200
Concept ID:
C1566164
Organic Chemical; Pharmacologic Substance
5.

Methylation

A chemical reaction in which a small molecule called a methyl group is added to other molecules. Methylation of proteins or nucleic acids may affect how they act in the body. [from NCI]

MedGen UID:
44400
Concept ID:
C0025723
Molecular Function; Natural Phenomenon or Process
6.

3-deazaneplanocin

MedGen UID:
12961
Concept ID:
C0047335
Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
7.

Short stature, idiopathic, X-linked

Idiopathic short stature is usually defined as a height below the third percentile for chronological age or minus 2 standard deviations (SD) of national height standards in the absence of specific causative disorders (Rao et al., 1997). For a discussion of genetic heterogeneity of quantitative trait loci for stature, see STQTL1 (606255). [from OMIM]

MedGen UID:
375584
Concept ID:
C1845118
Congenital Abnormality; Disease or Syndrome
8.

Histone deacetylase inhibitor

A substance that causes a chemical change that stops tumor cells from dividing. HDAC inhibitors are being studied in the treatment of cancer. [from NCI]

MedGen UID:
268200
Concept ID:
C1512474
Amino Acid, Peptide, or Protein; Enzyme; Pharmacologic Substance
9.

Neoplasm

A malignant tumor at the original site of growth. [from NCI]

MedGen UID:
227011
Concept ID:
C1306459
Finding; Neoplastic Process
10.

Tumor Initiation

The first stage of tumor induction by a carcinogen, consisting of subtle alteration of cells by exposure to a carcinogenic agent so that they are likely to form a tumor upon subsequent exposure to a promoting agent. (NCI) [from NCI]

MedGen UID:
154615
Concept ID:
C0598935
Neoplastic Process
11.

Heterogeneous

The production of the same or similar phenotypes (observed biochemical, physiological, and morphological characteristics of a person determined by his/her genotype) by different genetic mechanisms. There are two types: (1) allelic heterogeneity - when different alleles at a locus can produce variable expression of a condition; and (2) locus heterogeneity - the term used to describe disease in which mutations at different loci can produce the same disease phenotype. [from NCI]

MedGen UID:
67020
Concept ID:
C0242960
Organism Attribute
12.

Finding

The result of an examination or inquiry. [from NCI]

MedGen UID:
66215
Concept ID:
C0243095
Finding
13.

Clinical finding

clinical manifestations that can be either objective when observed by a physician, or subjective when perceived by the patient. [from CRISP]

MedGen UID:
19974
Concept ID:
C0037088
Sign or Symptom
14.

Adenoscan

MedGen UID:
810650
Concept ID:
C0718262
Organic Chemical; Pharmacologic Substance
15.

Plasma Cell Neoplasm

new abnormal plasma cells that grow by excessive cellular division and proliferation more rapidly than normal and continue to grow after the stimuli that initiated the new growth cease. [from CRISP]

MedGen UID:
368758
Concept ID:
C1959632
Neoplastic Process
16.

Molecular Mechanisms of Pharmacological Action

Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY. [from MeSH]

MedGen UID:
226255
Concept ID:
C1258062
Molecular Function
17.

Monoclonal Gammopathy

A laboratory test result indicating the presence of an abnormally high level of monoclonal immunoglobulins in the blood or urine. [from NCI]

MedGen UID:
210153
Concept ID:
C1136085
Neoplastic Process
18.

Vascular hemostatic disease

Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS. [from MeSH]

MedGen UID:
154721
Concept ID:
C0600502
Disease or Syndrome
19.

DNA Methylation

The process by which methyl groups are added to nucleotides in genomic DNA. [from NCI]

MedGen UID:
138191
Concept ID:
C0376452
Genetic Function; Molecular Function
20.

Mediator of inflammation

The endogenous compounds that mediate inflammation (AUTACOIDS) and related exogenous compounds including the synthetic prostaglandins (PROSTAGLANDINS, SYNTHETIC). [from MeSH]

MedGen UID:
66209
Concept ID:
C0243042
Pharmacologic Substance
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center